The Phase 2b trial study of NVX-CoV2373 will be conducted on about 2,665 healthy adults and will evaluate the safety and immunogenicity in about 240 medically stable, HIV-positive adults, the company said in a statement.
Subscribe to:
Post Comments (Atom)
-
The NCLT#39;s Ahmedabad bench has directed the RP to include GAIL in the list of creditors for both the companies.
-
"The (latest) investment will be used to grow the mobile esports format and establish presence in select overseas markets through its ...
-
Thirteen tier 2 and 3 cities register higher traffic in December than pre-COVID-19 levels.
No comments:
Post a Comment